Checkpoint Therapeutics Inc CKPT

$4.26 +0.03 (0.71%)

Valuation

Market cap
370,705,000
Revenue TTM
$40,000
Net income TTM
$-56,240,000
PE ratio
0.00
Forward PE
—
Profit margin
-140,600.01%
Debt to equity
0.00

Trading

Volume
8,666,800
Avg volume
1,808,080
Day's range
$4.23 – $4.28
Shares out
87,020,000
Stochastic %K
85%
Beta
1.18
Analysts
Sell
Price target
$4.45

Price

Company profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; an...

Show more

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. As of May 30, 2025, Checkpoint Therapeutics, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Industry
Biotechnology
Sector
Healthcare
Phone
781 652 4500
Website
https://checkpointtx.com
Address
95 Sawyer Road, Suite 110, Waltham, United States

Latest news

Stocktwits

Zellchair Oct 26, 3:05 PM
$FBIO $FBIOP $CKPT Sun Pharma’s Unolxcyt shows sustained cancer control in two year follow-up Read more at: https://pharma.economictimes.indiatimes.com/news/research-and-development/sun-pharmas-unolxcyt-shows-sustained-cancer-control-in-two-year-follow-up/135200580
0 replies
Zellchair Oct 23, 12:56 PM
$FBIO $FBIOP $CKPT Sun Pharma is set to present follow-up data for UNLOXCYT at ESMO tomorrow. Those who will be presenting the study sound positive. https://www.prnewswire.com/news-releases/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc-302918079.html
0 replies
Zellchair Oct 14, 2:13 PM
$FBIO $FBIOP $CKPT Another positive news that came in May (about a month after I closed my substack on Fortress) is the follow-up data for UNLOXCYT presented at ASCO 2026. In the updated long-term data, UNLOXCYT's competitive position is strengthened primarily by its sustained response rate (DOR) and its adverse event profile, rather than just the initial response rate (ORR). The data confirms highly durable responses and increasing complete response rates over time. It is also possible to interpret a clear safe edge against its two competitors with unusually low rates of severe immune-related adverse events (Grade ≥3 irAEs < 2%), offering a major advantage in elderly or fragile CSCC patients. https://www.prnewswire.com/news-releases/at-the-asco-2026-annual-meeting-sun-pharma-to-present-pivotal-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-302781880.html
1 replies
Jbaffs Oct 9, 3:20 PM
$CHRS I think I will make me more $$$ than all of this combined. Greatest trade sequence in my 40-yr Wall Street career. Loaded up on $CKPT at $1.65, bought out at $4.15. Rolled into $TSLA when they were burning dealerships at $225, sold at $400, rolled into $OMER at $3.65, up 600%. NOT STOCK ADVICE!
6 replies
SnowyDingo Aug 20, 4:59 PM
$LAB I have seen this pattern before for checkpoint $CKPT . Currently, given the limbo, it's a downward pressure to scoop up shares from retail who have no patience and trade with emotions. GTLA who are buying and holding.
0 replies
TwongStocks Jun 9, 11:50 AM
$CKPT Unlike the US, there is no fixed date for drug approvals in Europe. This is due to built in "clock stops" during the evaluation process. Typically, most drugs get approved around 1 year after positive validation. The two year deadline for the CVR is protection in case the approval takes longer than usual or runs into any sort of delay. But if they do not run into any serious delays, then we may see UNLOXCYT approval by next summer.
1 replies
TwongStocks Jun 9, 11:08 AM
$CKPT CHMP has now begun evaluating UNLOXCYT (Cosibelimab) for approval in Europe. Start of evaluation is May 21, 2026. This is the date the UNLOXCYT MAA received positive validation. The $0.70 CVR will payout if UNLOXCYT is approved within 2 years (by May 21, 2028) and the approved dose is once every 3 weeks. You can confirm the start date here. Download the 'Applications for new human medicines under evaluation' for June 2026: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
0 replies
Tott2022 Apr 30, 12:22 PM
$CKPT I am guessing Sun are gonna wait it out … and not have to pay up
1 replies